Table of Contents
non-blinded clinical nmn trial
A non-blinded clinical Nicotinamide Mononucleotide (NMN) trial has been conducted at the Clinical Trial Unit, Keio University School of Medicine in Japan on 10 healthy men aged between 40 and 60 years of age to ensure that there were no adverse side effects to taking NMN. The NMN used had a purity of between 96% and 97% according to a high-performance liquid chromatography (HPLC).
A non-blinded trial describes a clinical trial, or other experiment, in which the researchers know what treatments are being given to each study subject and the subjects involved know what treatments they are receiving.
This small human NMN trial achieved what it set out to establish: to demonstrate that the drug is safe and well tolerated at the dosage used on humans. This NMN trial did not set out to demonstrate the efficacy of NMN and given the small number of trial participants, the single dose, and the short study time, it was never going to do more than establish that the drug is safe for human use.
people excluded from the nmn trial
Volunteers with the following were excluded from the nmn trial:
- Previous history of diseases, but nothing specific described
- Malignant neoplasms, which means a tumor that is cancerous
- Serious infections, not specified, but maybe infections such as Influenza, an STD, hepatitis, HIV or MRSA
- Psychiatric disorders, again not specified, but maybe Bipolar disorder, anxiety disorders, PTSD or Schizophrenia
- Ophthalmic disorders, again not specified, but maybe Conjunctivitis, Cataracts, Glaucoma
- Allergic disorders, maybe asthma, food allergies, medication allergies
- Metabolic diseases
data recorded
During the NMN trial (for 5 hours after the administration) the researchers observed various biomarkers such as:
- Heart rate
- Blood pressure
- Oxygen saturation
- Body temperature
Urine was collected every 30 to 60 minutes for the first 2 hours after administration and at the end of the study. Blood was collected every 5 to 20 minutes for the first hour, followed by every 30 to 120 minutes for the next 4 hours.
Ophthalmic examinations (on the left eyes) were conducted (by registered ophthalmologists) on the day of intervention with those taking 100 and 500 mg of NMN before and after the administration covering visual acuity and functional visual acuity; this includes:
- The sharpness of the retinal focus within the eye,
- The health and functioning of the retina
- The sensitivity of the interpretative faculty of the brain
sleep statistics
During the NMN trial the quality of sleep was evaluated using the Pittsburgh Sleep Quality Index (PSQI) before and after the day of intervention.
no NMN in the blood samples
The researchers could not detect NMN in the blood samples taken in the study, but this is likely due to them being frozen, which may have degraded the NMN.
So, could freezing NMN also cause some degradation, or was it because the blood plasma acted as catalyst? Interesting, as keeping NMN refrigerated or frozen is now the norm in the NMN community. The report also mentions that NMN degrades rapidly in blood that was handled above 80 degrees centigrade (176 F).
the results
Results of ophthalmic examination and sleep quality score showed no differences before and after the intervention.
The only notable result was that bilirubin levels rose by 51.3% and glucose fell by 11.7% following dosage. However, it was concluded that those two changes were most likely associated with the overnight fast prior to taking NMN and the five-hour fast following administration.
During this NMN trial so significant changes were evident following the single dose, although this was to be expected, as the dosage range used of 100, 250, and 500 mg was fairly low.
The single oral administration of NMN was safe and effectively metabolized in healthy men without causing any significant harmful effects. So, oral administration of NMN was found to be feasible. These results are fairly unimpressive, but this is a good thing, it means the study was a success, in that NMN is safe for humans to take, well at least in the short term and in the doses used during the clinical trial.
trial limitations
This was not a placebo-controlled NMN trial, so the trail could not account for the placebo effect, that is, effects from treatment that do not depend on the treatment itself.
NAD+ and plasma NMN levels were not measured in this study.
This was a short term study, long-term trials of NMN should be conducted to further investigate the safety of NMN, and just as important, further trials on the efficacy of NMN as a new treatment for age-associated disorders should be conducted as soon as is practicable.
conclusion
There have been numerous animal studies; however, NMN trials on safety of NMN in humans were unclear, this NMN trial helps to confirm that. In general, the compound is safe and well tolerated; to that end, the trial can be considered a success. So, oral administration of NMN is feasible and could be a way of replenishing cellular NAD+ levels in an attempt to mitigate aging-related functional disorders in humans.
The next step for researchers will be to investigate the efficacy of NMN; suitable dosage and frequency protocols could then be established. It is certainly possible that NMN may fail during efficacy testing in humans, but this initial safety study has no bearing on that potential outcome.
There is currently an ongoing human NMN trial at the Brigham and Women’s Hospital in Boston from which efficacy data should be forthcoming, until that data is posted, no real conclusions, beyond NMN being safe for human consumption, can really be drawn.
Unfortunately, I had to close comments on the Blog because of spammers, more than fifty a day! If you have any questions, please leave them in the comments section of this video: https://bit.ly/2MId6UL